- Home
- SELF vs ANL Comparison
SELF vs ANL Comparison
Compare SELF & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SELF | ANL |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | 123 |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 62.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SELF | ANL |
|---|---|---|
| Price | $5.07 | $1.79 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.2K | ★ 1.3M |
| Earning Date | 11-07-2025 | 02-24-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $12,733,279.00 | N/A |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $31.63 | ★ N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $4.73 | $0.88 |
| 52 Week High | $5.89 | $2.75 |
Technical Indicators
Market Signals| Indicator | SELF | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 64.46 |
| Support Level | $5.02 | $1.48 |
| Resistance Level | $5.15 | $1.71 |
| Average True Range (ATR) | 0.10 | 0.21 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 37.14 | 80.95 |
Price Performance
Historical ComparisonAbout SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.